Nuclear expression of CDK4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma

Histopathology

Volumn 64, Issue 5, 2014, Pages 722-730

  Jiang, Qingping ^a,b   Mai, Chunping ^b   Yang, Huiling ^c   Wu, Qiangyun ^b   Hua, Shengni ^b   Yan, Chen ^b   Long, Yufei ^b   Zhang, Yajie ^a   Long, Xiaobin ^b,d   Fang, Weiyi ^b   Liu, Zhen ^a,b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

CDK4; Immunohistochemistry; Nasopharyngeal carcinoma; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 4; MESSENGER RNA; CDK4 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; VERY ELDERLY; YOUNG ADULT; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE 4; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84896108284     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12319     Document Type: Article

References (21)

1. Alajez NM, Shi W, Hui AB et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 2010; 1; e85.
2. Xia H, Cheung WK, Sze J et al. miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. J. Biol. Chem. 2010; 285; 36995-37004.
3. Yu X, Zhen Y, Yang H et al. Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 2013; 4; e634.
4. Wang S, Fang W. Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology 2011; 58; 217-224.
5. Zhen Y, Liu Z, Yang H et al. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis. 2013; 4; e872.
6. Luo WR, Wu AB, Fang WY et al. Nuclear expression of N-cadherin correlates with poor prognosis of nasopharyngeal carcinoma. Histopathology 2012; 61; 237-246.
7. Liu Z, Yang H, Luo W et al. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Histopathology 2013; 63; 362-370.
8. Fang W, Li X, Jiang Q et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J. Transl. Med. 2008; 6; 32.
9. Poomsawat S, Buajeeb W, Khovidhunkit SO et al. Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. J. Oral Pathol. Med. 2010; 39; 793-799.
10. Lindberg D, Hessman O, Akerström G et al. Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors. Neuroendocrinology 2007; 86; 112-118.
11. Wikman H, Nymark P, Väyrynen A et al. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosom. Cancer 2005; 42; 193-199.
12. Dobashi Y, Goto A, Fukayama M et al. Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma. Int. J. Cancer 2004; 110; 532-541.
13. Wu A, Wu B, Guo J et al. Elevated expression of CDK4 in lung cancer. J. Transl. Med. 2011; 9; 38.
14. Lu JW, Lin YM, Chang JG et al. Clinical implications of deregulated CDK4 and cyclin D1 expression in patients with human hepatocellular carcinoma. Med. Oncol. 2013; 30; 379.
15. Miliani de Marval PL, Macias E, Conti CJ et al. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 2004; 23; 1863-1873.
16. Han YK, Lee JH, Park GY et al. A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. Biochem. Biophys. Res. Commun. 2013; 430; 1329-1333.
17. Cheng M, Olivier P, Diehl JA et al. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 1999; 18; 1571-1583.
18. LaBaer J, Garrett MD, Stevenson LF et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997; 11; 847-862.
19. Hyter S, Bajaj G, Liang X et al. Loss of nuclear receptor RXRα in epidermal keratinocytes promotes the formation of Cdk4-activated invasive melanomas. Pigment Cell Melanoma Res. 2010; 23; 635-648.
20. Zhong Z, Yeow WS, Zou C et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. Cancer Res. 2010; 70; 2105-2114.
21. Ghazizadeh M, Jin E, Shimizu H et al. Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas. Respiration 2005; 72; 68-73.